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Background: We sought to examine the temporal variations in the rate of both bare-metal stent (BMS) and
drug-eluting stent (DES) use for off-label indications after the reports of an increased risk of very late stent
thrombosis in patientswith DES at the 2006 meeting of the European Society of Cardiology (ESC).
Hypothesis: To determine whether the decrease in use of DES has affected both on and off-label indications.
Methods: The study cohort included patients undergoing coronary intervention in a large regional registry,
the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Patient demographic and clinical
characteristics for patients with DES in the third quarter of 2006 (pre-ESC) were compared to those from
the fourth quarter of 2008 (post-guideline changes). Use of DES for off-label indications, such as ST-
segment elevation myocardial infarction (STEMI), in-stent restenosis (ISR), and saphenous vein graft (SVG)
interventions,were evaluated.
Results: The overall deployment of DES fell sharply from 83% pre-ESC to a plateau of 58% in the first quarter
of 2008. This corresponded to a rise in BMS use, while angioplasty procedures stayed the same. The STEMI
subgroup showed the most dramatic change, from 78% to only 36%. Off-label use in SVGs showed a similar
trend, from 74% to 43%. Drug-eluting stentdeployment for ISRwas less affected, though it also fell 25% (from
79%–56%).
Conclusions: The use of DES has fallen dramatically from June 2006 to December 2008, particularly for
nonapproved indications.Our study provides a real-world assessment of contemporary change in DES use in
response to the presentationof negative observational studies.
Introduction
After the first drug-elutingstent (DES) was approved by the
Food and Drug Administration (FDA) for use in the United
States in 2003, it quickly became the most commonly used
stent type in percutaneous coronary intervention (PCI).1
In September 2006, at the European Society of Cardiology
(ESC) meeting, an observational study including patients
who had received DES at a single institution, documented
an increased risk of very late stent thrombosis compared
to patients treated with bare-metal stents (BMS; 2.6% vs
1.3% over an 18 mo period).2 Several other studies provided
further evidence of an increased risk of very late stent
thrombosis with DES vs BMS.3,4 Subsequent consensus
statements from the FDA and the Society of Coronary
Angiography and Interventions (SCAI) in January 2007
recommended careful consideration of use of DES for off-
label indications.5 Media reaction was swift, condemning
DES technology as a potentially lethal heart device, and
inciting a wave of panic for patients previously treated.
In light of these recent studies, there have been signs
from industry data that the use of DES has dropped
dramatically. However, there has been no attempt to quantify
whether the decrease has occurred for approved or off-label
indications.Furthermore, it is unclear whethermore recent,
less sensationaltrials demonstratingDES efficacy and safety
have made an impact in DES use. In this study, we sought
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Clinical Investigations continued
to examine the temporal variations in the rates of both BMS
and DES use for off-label indications in a statewide registry.
Methods
Subjects
The study cohort for our analysis included patients
undergoingPCI in a large regional registry of contemporary
PCI, the Blue Cross Blue Shield of Michigan Cardiovascular
Consortium (BMC2). The details of the registry and of the
data collection process have been described elsewhere.6 – 9
Briefly, procedural data on all patients undergoing
elective and nonelective PCI at participating hospitals
were collected using standardized data collection forms.
Baseline data included clinical, demographic, procedural,
and angiographic characteristics, as well as, medications
used before, during, and after the procedure, and in-hospital
outcome. All data elements were prospectively defined and
the protocol was approved by the local institution review
board at each institution. The data was collected by a
dedicated staff member and forwarded to the coordinating
center. Medical records of all patients undergoing coronary
artery bypass grafting,or of patientswho died in the hospital
were reviewed to ensure data accuracy.A further 2% of cases
were randomly selected for audit.
The BMC2 database was queried for the total use of
DES, BMS, and angioplasty alone over the study period
of January 2006 to December 2008. Patient demographic
and clinical characteristics for patients given DES in the
third quarter of 2006 (pre-ESC) were compared to those
from the first quarter of 2008, when the nadir post-guideline
changes were reached. Furthermore the median rate of
DES use for all patients at each individual participating
hospital was determined for the study period. Use of
DES for off-label indications, such as ST-segment elevation
myocardial infarction (STEMI), in-stent restenosis (ISR),
and saphenous vein graft (SVG) interventions, were also
reported. Finally, we evaluated the trends in use of DES
in diabetic and elderly (≥80 yrs old) patients undergoing
intervention.
Statistical Analysis
Patient characteristics, hospital data, and DES use were
reported as frequencies for categorical data and means
for continuous data. All comparisons were performed using
SAS software,with a P value of <0.05 consideredstatistically
significant. The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agree to the manuscript as written.
Results
The study cohort included 79 388 patients undergoing
PCI between January 2006 and September 2008. Patient
demographic, clinical, and preprocedural data for patients
in the pre-ESC era as compared to the last quarter of the
study period are listed in Table 1. Among patients treated
with DES in the third quarter of 2006 vs the fourth quarter
of 2008, there were fewer patients with a history of obesity
(BMI ≥ 30) and hypertension.Conversely, there were more
DES patients in the third quarter of 2006 with significant
valve disease and recent gastrointestinal bleeding (<30 d
prior). Preprocedural clinical characteristics also differed
between the third quarter of 2006 and the first quarter of
2008 as moreemergencyPCI, cardiogenicshock,and visible
thrombus was found in the earlier period (Table 1).
The overall deployment of DES vs BMS heavily favored
DES use initially, until it fell sharply after September 2006
(Figure 1). A plateau of 57% DES use was reached by
December 2007. The fourth quarter of 2007 was a nadir
for the usage of DES, with a gradual rise though 2008.
The reduction in the use of DES corresponded to a rise in
BMS use, while angioplasty procedures stayed the same.
The median DES use at each participating hospital was also
compared over time (Figure 2). Though DES use at each
institution was at a relatively similar rate at the beginning of
the study time period, by the beginning of 2007 there was
a greater variation in the proportion of patients treated with
DES at a given hospital.
Off-label Indications
The study cohort was then analyzed by 3 off-label
indications, as well as 2 special clinical populations. The
STEMI subgroup showed the most dramatic change, from
78% use pre-September 2006, to only 36% at the tail end of
the study period (Figure 3). Off-label use in SVGs showed
a similar trend, from 74% to 43% (Figure 4). Drug-eluting
stent deployment for ISR was less affected, though it also
fell more than 25% (from 79%–56%) through March 2008
(Figure 5). Simultaneously, use of angioplasty for patients
with ISR increased from 3% at the beginning of the study
period, to as high as 14% by March 2008.
Special populations: In diabetics, DES use dropped from
83% to 58%. Similarly, DES use fell from 78% in the first
quarter of 2006 to 46% in the first quarter of 2008 in patients
>80 years old.
Discussion
In April 2003, the FDA approved sirolimus-eluting stents
(SES Cypher, Cordis Corporation, Bridgewater, NJ) for
use in patients with coronary artery disease. Approval for
paclitaxel-eluting stents quickly followed in March 2004. The
use of DES expanded beyond FDA-approved indications,
and off-label use, such as in acute coronary syndrome and
SVG disease, grew at the same rapid pace despite the lack
of clinical trials demonstrating safety and efficacy in these
patient populations.
In September 2006, at the ESC meeting, an observa-
tional study was presented which revealed a 0.6% per year
increased risk of very late stent thrombosis in patients
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N= 4826 p value
Historical Variables
Male 3165 (65.3%) 2786 (65.1%) 0.86
Age ≥ 80 years old 556 (11.5%) 491 (10.2%) 0.04
Current Smoking 1215 (25.1%) 1171 (24.3%) 0.37
Obese (BMI ≥ 30) 2125 (45.2%) 2293 (48.7%) 0.0006
Hypertension 3980 (82.1%) 4099 (84.9%) 0.0002
Previous MI 1674 (34.5%) 1656 (34.3%) 0.83
Diabetes 1673 (34.5%) 1787 (37.0%) 0.01
CHF 713 (14.7%) 670 (13.9%) 0.25
PVD/CVA 1269 (26.2%) 1201 (24.9%) 0.15
Dialysis dependent renal failure 81 (1.7%) 74 (1.5%) 0.59
Significant valve disease 219 (4.5%) 152 (3.2%) 0.0008
Recent GI bleed 107 (2.2%) 35 (1.1%) <0.0001
Atrial fibrillation 400 (8.3%) 419 (8.7%) 0.44
Cardiac arrest 63 (1.3%) 53 (1.1%) 0.36
PCI 2093 (43.2%) 2275 (47.1%) <0.0001
CABG 880 (18.2%) 921 (19.1%) 0.24
COPD 848 (17.5%) 856 (17.7%) 0.75
Presenting Variables
Emergency PCI 605 (12.5%) 476 (9.9%) <0.0001
Current MI (<7 days prior) 1309 (27.0%) 1317 (27.3%) 0.75
Cardiogenic shock 69 (1.4%) 44 (0.9%) 0.02
EF < 50% 1393 (28.7%) 1252 (25.9%) 0.002
CTO 92 (1.9%) 81 (1.7%) 0.42
Restenosis 393 (8.1%) 483 (10.0%) 0.001
Thrombus 582 (12.0%) 395 (8.2%) <0.0001
MI=myocardial infarction, CHF= congestive heart failure, PVD= peripheral vascular disease, CVA= cerebral vascular accident, PCI= percutaneous
coronary intervention, CABG= coronary artery bypass grafting, COPD= chronic obstructive pulmonary disease, EF= ejection fraction, CTO= chronic total
occlusion. Dialysis-dependent renal failure wasdefined as those patients requiring peritoneal or hemodialysis. Thrombus was defined as visible thrombus
at the time of initial angiography.
receiving DES. Very late stent thrombosis is a serious
complication of DES use, with 60% of patients presenting
with either STEMI or death.10 In light of these find-
ings, revised guidelines from the SCAI and the FDA
advised caution in the use of DES and in assessing
appropriateness of patients for prolonged dual antiplatelet
therapy.4
In the present study, we sought to evaluate the impact
these presentations and publications had on the use of
DES through a statewide registry. A sharp decline in
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Figure 1. Stent use among all patients undergoing PCI from January 2006
to March 2008. Abbreviations: DES, drug-eluting stent; BMS, bare-metal
stent, PCI, percutaneous coronary intervention; POBA, balloon
angioplasty alone, Q1 06, January to March 2006; Q2 06, April to June
2006;Q3 06, July to September 2006;Q4 06, October to December 2006;
Q1 07, January to March 2007;Q2 07, April to June 2007;Q3 07, July to
September 2007;Q4 07, October to December 2007; Q1 08, January to
March 2008; Q2 08, April to June 2008; Q3 08, July to September 2008;












































Figure 2. Median rate of DES use across all participating hospitals for any
patient undergoing PCI. Abbreviations: DES, drug-eluting stent; BMS,
bare-metal stent, PCI, percutaneous coronary intervention; POBA, balloon
angioplasty alone, Q1 06, January to March 2006; Q2 06, April to June
2006;Q3 06, July to September 2006;Q4 06, October to December 2006;
Q1 07, January to March 2007;Q2 07, April to June 2007;Q3 07, July to
September 2007;Q4 07, October to December 2007; Q1 08, January to
March 2008; Q2 08, April to June 2008; Q3 08, July to September 2008;
Q4 08, October to December 2008.
DES use, in both the total population, which included
stable and ACS patients, as well as a decline in the use



























































Figure 3. Stent use among patients presenting with STEMI.
Abbreviations: DES, drug-eluting stent; BMS, bare-metal stent, PCI,
percutaneous coronary intervention; POBA, balloon angioplasty alone, Q1
06, January to March 2006; Q2 06, April to June 2006;Q3 06, July to
September 2006; Q4 06, October to December 2006;Q1 07, January to
March 2007;Q2 07, April to June 2007;Q3 07, July to September 2007;Q4
07, October to December 2007;Q1 08, January to March 2008; Q2 08,
April to June 2008; Q3 08, July to September 2008; Q4 08, October to
December 2008; STEMI, ST-segment elevation myocardial infarction.
DES use across all patients included in our analysis
may be related to fear of the catastrophic outcomes of
patients who suffer stent thrombosis, including STEMI
and death. Additionally, increased media coverage and
public awareness of side effects of prescription drugs
and complications with medical devices may have fueled
a more precipitous drop in the use of DES. However,
the decline in DES use was not uniform, with marked
variability in DES use between hospitals by the end
of the first quarter of 2008. More recently, usage of
DES in PCI appears to be leveling off, perhaps in
part to recent reports which demonstrated no significant
increase in stent thrombosis with DES when compared to
BMS.11 – 13
Off-label use of DES came under particular scrutiny
following clinical statements made by professional soci-
eties. We chose patients with STEMI, SVG disease, and
ISR as representative subgroups of off-label indications
to further evaluate the impact of the landmark trials on
DES use. Though a decline after the third quarter of 2006
was seen among all the subgroups, the most pronounced
decline was seen in patients with STEMI. This most likely
represents a higher level of concern regarding thrombus
burden and general preinflammatory state at the time of
intervention. This is further supported by the changing
patient clinical characteristics pre-ESC and post-ESC, with a
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Figure 4. Stent use in patients undergoing vein graft intervention.
Abbreviations: DES, drug-eluting stent; BMS, bare-metal stent, PCI,
percutaneous coronary intervention; POBA, balloon angioplasty alone, Q1
06, January to March 2006;Q2 06, April to June 2006; Q3 06, July to
September 2006;Q4 06, October to December 2006; Q1 07, January to
March 2007; Q2 07, April to June 2007; Q3 07, July to September 2007;Q4
07, October to December 2007;Q1 08, January to March 2008;Q2 08,
April to June 2008; Q3 08, July to September 2008; Q4 08, October to
December 2008.
statistically significant drop in the percentage of patients
with visible thrombus on angiography who received a
drug-eluting stent. The emergent pace of primary PCI in
STEMI may also limit the physicians’ ability to identify
patient comorbidities or financial difficulties which could
make compliance with long-term dual antiplatelet therapy
difficult.
There are limiteddata evaluatinguse of DES in vein grafts
and concerns have been raised regarding the interaction of
the drug-eluting stent with the aggressive atherosclerosis
typical of vein graft disease. This concern may have played
a part in the corresponding drop in DES use among the
subset of patients undergoing PCIs in the BMC2 registry.
Though also an off-label indication, a less well understood
decline in DES in patients with restenosis was also seen,
as well as an increase in angioplasty alone, from 4% to 14%
by the first quarter of 2008. Patients with restenosis are
at the greatest risk of subsequent restenosis and DESs
have demonstrated marked benefits in this population.14 A
decline in DES use may seem a bit counterintuitive in this
subset.
The 2 patient populations that are more likely to benefit
from DES use also demonstrated a puzzling decline in DES
use. The dramatic efficacy of DES in the presence of diabetes
has been well established.15,16 However, there was a similar


























































Figure 5. Stent use in restenotic lesions. Abbreviations: DES, drug-eluting
stent; BMS, bare-metal stent, PCI, percutaneous coronary intervention;
POBA, balloon angioplasty alone, Q1 06, January to March 2006;Q2 06,
April to June 2006;Q3 06, July to September 2006;Q4 06, October to
December 2006;Q1 07, January to March 2007;Q2 07, April to June 2007;
Q3 07, July to September 2007; Q4 07, October to December 2007;Q1 08,
January to March 2008; Q2 08, April to June 2008; Q3 08, July to
September 2008; Q4 08, October to December 2008.
study. Finally, DES use in patients over 80 years old fell
by almost half, which could be in part due to concern over
long-term dual antiplatelet and thus increased bleeding risk
in these patients.
Our study provides an example of a possible disconnect
between emerging clinical evidence and clinical practice. In
the past, appropriate clinical use of proven therapies has
been observed in response to widely published, compelling
clinical evidence, albeit the pace of adoption of such
advances in care historically has been very slow.17 Our
data would suggest that new device use may demonstrate a
different pattern, with rapid changes in practice patterns
in response to partial information demonstrating newly
identified risks driving broad changes in device use, only
some of which are based on newly reported evidence. This
theory is further supported by data from the CRUSADE
and ACTION-GWTG registries, which found a similar
decline in DES use, though data was limited to patients
presenting with non–ST-segment elevation myocardial
infarction.18
When DESs were introduced, they were hailed as one of
the greatest breakthroughs in cardiovascular medicine by
both the medical press and the lay press. Physicians initially
overwhelmingly adopted DES with limited data to support
use in off-label patient populations. Subsequently and likely
based primarily on the report from small observational
studies, we observed a dramatic decline in use of DES
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Clinical Investigations continued
even in patient populations where the stents have been
demonstrated to be particularly efficacious. This decline
preceded the publication of the negative data in peer-
reviewed literature and seems to have been fuelled by the
negative publicity in the lay press. Despite a multitude of
more recent data, DES use has yet to reach 2006 rates. Our
study thus provides a glimpse into the changing patterns
of uptake of a therapy that is widely covered by the lay
press.
Study Limitations
This study was limited to an assessment of pre-PCI
and procedural characteristics, and did not include an
assessment of long-term outcomes such as late stent
thrombosis. Our data suggest, but do not prove, a
relationship between DES use and media reporting.
Conclusion
In this large multicenter registry, overall DES use has fallen
dramatically from June 2006 to December2008, though with
marked variability in utilization rates between hospitals.
The most pronounced decreased use of DES has occurred
for nonapproved indications, including STEMI and SVG
disease, but also seems to have occurred in populations
where DES may be particularly efficacious. Our study
provides a real-world assessment of contemporary change
in DES use in response to the presentation of negative
observational studies.
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